

Covid-19: an uncertain future for mortality

The Covid-19 pandemic has had a dramatic impact on mortality rates. The effects of this will flow through into pension scheme funding levels as member experience is taken into account, but trustees will also need to form a view on how the pandemic will affect future mortality rates and improvements.

Originally published April 2022 and updated June 2023.




Impact of Covid-19 on future mortality

The term 'mortality improvement' refers to the extent by which the mortality rates of a given population decrease from one year to the next – positive improvements give increases in life expectancy. Even before the pandemic struck there was a great deal of uncertainty surrounding the direction of future mortality improvements. What we've observed over the past two years has only exacerbated that.

The pandemic has undoubtedly changed the landscape for future mortality - listed below are a number of medical, economic and social factors which will determine future mortality improvements. In order to help steer through the uncertainty, we have carried out analysis of plausible (but simplified) future scenarios to determine what each might mean for future mortality improvements and life expectancies. The results of the scenarios are summarised below and discussed further overleaf.





The percentages shown for each scenario below represent the impact on life expectancy and liability values, relative to pre-pandemic expectations, for a male aged 65.

INCREASED LIFE EXPECTANCY?


- Advancements in vaccine science
- Greater public health
 awareness
- Stronger surviving population
- Healthier lifestyle through
 home working
- Better prepared for the next pandemic





Scenario analysis

Scenario 1 – Quickly back to normal



The effect of Covid-19 is isolated to 2020 and 2021. We will have suffered two 'lost years' but then the successful vaccine programme means that mortality rates return to normal and improvements return to pre-pandemic trends.

As a result of two years with no improvements, mortality rates remain slightly higher than expectations before the pandemic.

Life expectancies fall by around 0.7%.

KEY:


Pre-pandemic expectations for improvements in mortality over time.

The line initially follows mortality improvement trends prior to the pandemic, before converging to a long-term expectation of future improvements (assumed to be 1.5% p.a. in these illustrations).

The black line represents the 2020 Covid-19 baseline. This shows no further improvements in mortality, in line with experience in 2020.

Covid-19: an uncertain future for mortality | April 2022

Scenario 2 – Pandemic effects linger for several years



Although Covid-19 ceases to be a significant cause of death, the indirect effects from delayed diagnoses and economic recession mean that mortality rates remain higher than normal. Backlogs in the healthcare system persist for several years, with continued delays in diagnosing and treating other conditions such as cancers and routine cardiovascular surgeries.

No mortality improvements are experienced for seven to eight years after the onset of the pandemic, before reverting back to a similar trend expected prior to the pandemic.

Life expectancies fall by around 2.2%.


Difference in improvement rates versus illustrative prepandemic expectations for each scenario. The larger the shading, the greater the impact on future life expectancies.

Red shading indicates how overall mortality has increased relative to pre-pandemic expectations; green shading (as seen in Scenario 4) indicates how relative mortality has decreased.





Scenario 3 – Covid-19 is the new flu



Covid-19 never fully goes away and evolving strains continue to infect people for the foreseeable future, but with a lesser mortality impact. Furthermore, mortality rates are impacted by the effects of Long Covid for those who do survive. In the nearer term, the backlog in the healthcare system still takes years to resolve, meaning delays in treating and diagnosing other conditions.

No mortality improvements are experienced for seven to eight years after the onset of the pandemic, and when they do start to revert back to pre-pandemic levels they do not quite reach the same heights as previously expected.

Life expectancies fall by around 2.9%.


KEY:

Pre-pandemic expectations for improvements in mortality over time.

The line initially follows mortality improvement trends prior to the pandemic, before converging to a long-term expectation of future improvements (assumed to be 1.5% p.a. in these illustrations).

The black line represents the 2020 Covid-19 baseline. This shows no further improvements in mortality, in line with experience in 2020.

Scenario 4 – Good habits from the pandemic



Life expectancy improves as a result of measures taken to stop the spread of Covid-19. There is greater public health awareness and hygiene, and developments in vaccine science mean we are better prepared to fight off future pandemic and diseases.

After two lost years, mortality improvements creep higher than prepandemic expectations and then remain slightly above pre-pandemic expectations over the long-term, due to lessons learnt from the pandemic.

Life expectancies rise by around 0.8%.

Difference in improvement rates versus illustrative prepandemic expectations for each scenario. The larger the shading, the greater the impact on future life expectancies.

Red shading indicates how overall mortality has increased relative to pre-pandemic expectations; green shading (as seen in Scenario 4) indicates how relative mortality has decreased.






Other sources of uncertainty

Even in a world without Covid-19, there was plenty of uncertainty regarding future mortality improvements, particularly surrounding breakthroughs in medical treatments (or lack thereof). These sources of uncertainty still remain now and provide a context in which to consider the scenarios above.

We have considered plausible scenarios for medical advances in the future, which might serve as reasonable bounds of uncertainty in future mortality improvements. The impacts on life expectancies are shown below and are considerably higher than those expected under the Covidrelated scenarios above.



Summary

There are a number of factors which will drive the future outcome for mortality improvements following the change in landscape over the past two years. Trustees will need to make a decision on both the directional influence that Covid-19 will have on future improvements and the magnitude of any impact.

If trustees do think that the impact of the Covid-19 pandemic will be a reduction in life expectancies, they will still need to consider how much prudence to incorporate in their funding assumptions. The Pensions Regulator's 2021 Funding Statement suggested that trustees adopting weaker mortality assumptions should have a contingency plan in case they do not materialise in the future. Whilst it might therefore be tempting to ignore the potential Covid-19 impact on the grounds of prudence, there may be consequences from being too prudent; for example, where funding affordability drives the level of risk in the investment strategy. Consideration may also need to be given to transfer value bases and actuarial factors to ensure that these appropriately reflect the trustees' bestestimate view on future mortality.





UPDATE FOLLOWING 2022

Mortality over 2022: a clearer direction?

The initial briefing note set out four possible scenarios for how life expectancies may be impacted by the Covid-19 pandemic, relative to pre-pandemic expectations. With 2022 now behind us, we can consider how the experience through the year compared with those scenarios presented.


Mortality over 2022 was 4.5% higher than prepandemic levels, demonstrating that the effects of the pandemic were still lingering.

During 2020 and 2021 there were two major 'waves' of deaths from Covid-19, with mortality rates peaking dramatically in spring 2020 and winter 2020/21. However, in 2022 there was no clearly defined peak as such, with mortality rates broadly in line with pre-pandemic levels in early months but significantly higher thereafter.

Covid-19: an uncertain future for mortality | June 2023

20,000 15,000 10,000

5,000



Weekly registered deaths (3-week average) 2020-2022







Excess deaths (smoothed): split of Covid and non-Covid deaths

Covid-19: an uncertain future for mortality | June 2023

While mortality rates over 2022 were worse than prepandemic rates, this was not necessarily driven by direct Covid-related deaths as illustrated in the chart to the left. Deaths directly related to Covid-19 continued through the year, at around 1,000 deaths per week during the first third of the year (when overall deaths were at their lowest) and then dropping to around 300-700 per week from May through to the end of the year (when overall deaths were at their highest).

It was therefore the 'non-Covid excess' deaths during the second half of 2022 that drove the increased overall mortality rate.

Key contributors to this were deaths from a range of heart and circulatory diseases, cirrhosis, and diabetes. While these are common causes of death in the UK in any year, the heightened rates are likely a sign of the NHS backlog built up during the pandemic years. This suggests that the pandemic effects may linger for several years yet (as per <u>Scenario 2</u> illustrated on page three), but how this will play out in the future is still uncertain.





CMI 2022 model

Many schemes use the Continuous Mortality Investigation's (CMI) model to calculate future life expectancies. The 2020 and 2021 versions of the default CMI model made no allowance for the possible effects of the pandemic, assuming that future mortality would be like pre-pandemic expectations. However, considering the experience over 2022, **the CMI has confirmed that its 2022 version of the model will assume that life expectancies for typical pensioners will be reduced by around 2-3% compared to the pre-pandemic version of the model.** As with the 2020 and 2021 versions, users can amend the parameters to assume a different effect if desired. The 2022 model will be released in summer 2023, and further considerations around application of the model can be found in this <u>blog written by Will Rice</u>.

The Pension Regulator's (TPR's) updated guidance

Since we published our initial briefing note, TPR has softened its guidance on setting mortality assumptions. In the 2023 Annual Funding Statement, TPR acknowledges that "mortality in 2022 onwards may be more indicative of future mortality than previous years, and if so, this may suggest lower future life expectancies." However, TPR also notes that there are "differing views" and the new trends need to be interpreted with caution.

Summary

Based on how mortality rates have developed over the past few years, we expect that many trustees will be considering an update to their mortality assumptions – particularly where current assumptions make no allowance for the effect of the pandemic. Adopting the core CMI_2022 model for future mortality improvements is expected to lead to reduction in life expectancies of the order of 2-3%, broadly in line with the impact we estimated in Scenario 2 where the effect of the pandemic lingers for several years.









Please contact your Barnett Waddingham consultant if you would like to discuss any of the above topics in more detail. Alternatively get in touch via the following:

⊠ info@barnett-waddingham.co.uk

\u03e9 0333 11 11 222
 \u03e9
 \u02e9
 \u03e9
 \u03e9

www.barnett-waddingham.co.uk

Barnett Waddingham LLP is a body corporate with members to whom we refer as "partners". A list of members can be inspected at the registered office. Barnett Waddingham LLP (OC307678), BW SIPP LLP (OC322417), and Barnett Waddingham Actuaries and Consultants Limited (06498431) are registered in England and Wales with their registered office at 2 London Wall Place, London, EC2Y 5AU. Barnett Waddingham LLP is authorised and regulated by the Financial Conduct Authority. BW SIPP LLP is authorised and regulated by the Financial Conduct Authority.

Covid-19: an uncertain future for mortality

